UK-based Medovate, a medical machine growth firm, has introduced an settlement with AKSIA Healthcare FZC to distribute its SAFIRA (SAFer Injection for Regional Anaesthesia) product vary in Saudi Arabia, the UAE and Bahrain.
SAFIRA is a Class II medical machine system which is reworking regional anaesthesia around the globe by making it a one-person process and incorporating a built-in security system to robotically restrict injection strain.
Following regulatory approvals, SAFIRA will grow to be obtainable by means of AKSIA Healthcare FZC in these three key Center East markets.
Developed in collaboration with clinicians from the Nationwide Well being Service (NHS) within the UK, the award-winning system places full management of the injection within the arms of the anaesthesiologist, liberating up the beforehand required assistant to hold out different duties. The system additionally helps to enhance affected person security by lowering the chance of nerve injury because it robotically limits injection strain to lower than 20psi.
Talking about their partnership with AKSIA Healthcare FZC Chris Rogers, Gross sales and Advertising Director, at Medovate, stated: “We’re delighted to be working with Aksia Healthcare FZC as we now work in direction of launching SAFIRA in these key markets. This settlement will enable sufferers and clinicians in each governmental and personal amenities to learn from the worth that SAFIRA brings to safer regional anaesthesia.”
Ahmed Sallam, Managing Director of AKSIA Healthcare FZC, added: “We’re happy to enter this partnership with Medovate to distribute SAFIRA throughout the United Arab Emirates, Saudi Arabia and Bahrain. There’s a actual want for a system like this, not solely to assist enhance affected person security but additionally to have a big impact on the best way regional anaesthesia is carried out by anaesthesiologists.”
SAFIRA was demonstrated reside at Arab Well being 2022 by one in every of its inventors, Dr Emad Fawzy, a marketing consultant anaesthesiologist, on the flagship Sheikh Khalifa Medical Metropolis in Abu Dhabi.
Dr Fawzy added: “I’m delighted that this pioneering UK-developed medical system will quickly be obtainable to make use of throughout extra Center East states. The system has already been utilized by clinicians the world over and suggestions has been overwhelmingly optimistic. We predict a big demand for it from Center Jap clinicians because it has a big impact on affected person security.”
SAFIRA has the potential to make a major impression by making injection throughout regional anaesthesia safer, lowering the chance of nerve harm from injection at excessive pressures. It gained the UK HSJ ‘Affected person Security Innovation of the 12 months’ award in 2021.
Current publications, together with a joint assertion by the American Society of Regional Anaesthesia and Ache Administration (ASRA) and the European Society of Regional Anaesthesia and Ache Remedy (ESRA), have beneficial regional anaesthesia be thought-about at any time when surgical procedure is deliberate for a suspected or confirmed COVID-19 affected person. It’s because it preserves respiratory perform and avoids the potential for transmission of COVID-19 in comparison with normal anaesthesia.
As demand for such procedures continues to develop steadily, SAFIRA has the potential to make a major impression, together with within the Center East. In Saudi Arabia in 2020 there have been just below 3,500 practising anaesthesiologists and analysis performed in 2012 confirmed 88% of anaesthesiologists in Saudi Arabia have been practising regional anaesthesia each day. The worldwide ultrasound guided regional anaesthesia market is rising and is forecast to register a CAGR of 5.8% by means of to 2028.